Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
RLYB - Rallybio Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Stock News
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—EWCZ, STEL, RLYB, and CTRA
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio shareholders are expected to own approximately 3.65% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the me.
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
Rallybio Corporation (NASDAQ: RLYB) shares are up Monday following a merger agreement with Candid Therapeutics Inc.
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Rallybio Corporation (NASDAQ: RLYB) and Candid Therapeutics, Inc. Upon completion of the proposed transaction, Rallybio shareholders are expected to own approximately 3.65% of the combined company. Halper Sadeh encourages Rallybio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpers.
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction (the "Merger"). Upon completion of the Merger, the combined company expects to.
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
NEW HAVEN, Conn. & SAN DIEGO--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) ("Rallybio") and Candid Therapeutics, Inc. ("Candid"), a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, today announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction (the "Merger"). Upon completion of the Merger, the combined company expects to.
Short Interest in Rallybio Corporation (NASDAQ:RLYB) Declines By 72.5%
Rallybio Corporation (NASDAQ: RLYB - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 13th, there was short interest totaling 38,974 shares, a decrease of 72.5% from the January 29th total of 141,643 shares. Currently, 0.8% of the shares of the company are short
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026
Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial evaluating RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor, in development for patients with complement-mediated.
Stock Splits Matter: What’s Coming Up This Month?
Here is a look at why companies split their stocks and why it matters. Upcoming splits worth keeping an eye on include one by Southern Copper..
Rallybio Announces Reverse Stock Split of Common Stock
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated Certificate of Incorporation (the “Amendment”) to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is intended to give Rallybio greater flexibility in considering and planning for futur.